Compare Illumina, Inc. (ILMN) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Altria Group Inc — how do they compare? Illumina, Inc. trades at $182.09 (market cap $27.94B), while Altria Group Inc trades at $74.56 (market cap $124.67B). The key difference: Altria Group Inc is far larger — about 4.5× Illumina, Inc.'s market cap, and Altria Group Inc pays a 5.68% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MO | |
|---|---|---|
Market Cap | $27.94B | $124.67B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $74.66 |
52-Week Low | $91.00 | $54.72 |
Enterprise Value | $29.33B | $145.75B |
Dividend Yield | — | 5.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Altria (MO) trades at $74.14, down slightly by 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 39.52% net income margin and consistent dividend payments, including a recent $1.06 dividend declared for July 2026. Revenue remains stable around $20.1B for 2025, though net income dipped to $6.95B from prior peaks. Analyst consensus is predominantly bullish with 16 buys and a $71.00 price target.
Outlook: MO offers a high-yield dividend appeal and defensive positioning amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Earnings beats in recent quarters provide support, though debt levels and competitive shifts in nicotine products warrant caution for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
